Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
111.77
-2.70 (-2.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biontech Se ADR
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
64
65
Next >
Why Novavax Shares Are Getting Hammered After Moderna, Pfizer And BioNTech News
August 31, 2022
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 6.76% to $32.84 Wednesday afternoon in possible reaction to competitor Moderna Inc (NASDAQ: MRNA) receiving FDA authorization for emergency use...
Via
Benzinga
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
August 31, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer, Moderna Nab FDA Authorization For Updated Covid Boosters
August 31, 2022
Boosters are recommended two months out from the last shot.
Via
Investor's Business Daily
Benzinga Before The Bell: Tesla Sues Louisiana Automobile Dealers Association, Will iPhone 14 Feature Satellite Connectivity?, Netflix Denies $7 To $9 Ad-Supported Plan And Other Top Financial Stories Tuesday, August 30
August 30, 2022
Reuters Taiwan’s China Airlines Orders 16 Boeing 787s
Via
Benzinga
US Stock Futures Higher Ahead Of Economic Data, Fed Speakers
August 30, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade as investors digested comments from Federal Reserve Chairman Jerome Powell. Markets closed lower again on Monday, with the...
Via
Benzinga
Pfizer-BioNTech, Moderna Set To Get FDA Nod For Omicron Booster Shots As Early As Wednesday: Report
August 30, 2022
Booster shots for Omicron variants of the novel coronavirus could officially be made available in the U.S. just after Labor Day, Politico reported on Monday.
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via
Benzinga
Pfizer/BioNTech Complete European Submission For Omicron Subvariant Adapted Vaccine
August 26, 2022
Via
Benzinga
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
August 26, 2022
From
Pfizer Inc.
Via
Business Wire
Moderna Claims Pfizer, BioNTech Stole Its Patented Tech In Covid Shot
August 26, 2022
The lawsuit alleges Comirnaty violates Moderna's patents from 2010-16.
Via
Investor's Business Daily
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
August 26, 2022
Moderna Inc (NASDAQ: MRNA) has
Via
Benzinga
Pfizer And Moderna Are In A Race With Omicron; Will The Vaccine Stocks Be Too Late?
August 26, 2022
The companies hope to launch updated boosters this fall. This is what experts think of their prospects.
Via
Investor's Business Daily
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
August 24, 2022
In a Reuters report, AstraZeneca Plc's (NASDAQ:
Via
Benzinga
Moderna Asks FDA To Sign Off On Its Updated Covid Booster Shot
August 23, 2022
Moderna put the finishing touches on its FDA filing Tuesday, trailing its rivals by a day.
Via
Investor's Business Daily
Pfizer/BioNTech's COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers
August 23, 2022
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have
Via
Benzinga
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
August 23, 2022
From
Pfizer Inc.
Via
Business Wire
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
Via
Benzinga
Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here's Who May Be Rolling Them Out
August 22, 2022
Via
Benzinga
Face Of US COVID-19 Response, Dr Anthony Fauci To Retire In December
August 22, 2022
Via
Benzinga
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
August 22, 2022
From
Pfizer Inc.
Via
Business Wire
Benzinga Before The Bell: Apple Employees Resist Calls For Return-To-Office, Tesla About To Hike FSD Prices Again, MGM China Injects $594M Into Macau Unit And Other Top Financial Stories Monday, August 22
August 22, 2022
Reuters Vodafone To Sell Hungarian Business For $1.8B: Report
Via
Benzinga
Canada OKs Pfizer COVID-19 Booster For Kids Aged 5-11 Years
August 22, 2022
Via
Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
August 19, 2022
How they handle an upcoming shift in payments will be telling for their tailwind.
Via
Investor's Business Daily
Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022
August 17, 2022
Via
Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
August 17, 2022
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.
Via
InvestorPlace
A Look Into Healthcare Sector Value Stocks
August 15, 2022
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...
Via
Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
August 15, 2022
The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year...
Via
Benzinga
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
August 12, 2022
The major indexes continued to advance, despite some key warnings.
Via
Investor's Business Daily
Pharmaceutical Companies Report Gearing Up To Combat COVID Variants This Fall
August 11, 2022
The more contagious omicron BA.4 and BA.5 COVID-19 variants are dominant in all parts of the United States, making up more than 70% of infections.
Via
Benzinga
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
August 11, 2022
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
64
65
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.